[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"remission\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:remission":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,108,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100595302","association-between-exercise-patient-reported-outcomes-and-clinical-events-in-adult-cancer-survivors-100595302",false,"NCT07030686","Association Between Exercise, Patient-Reported Outcomes, and Clinical Events in Adult Cancer Survivors","Inclusion Criteria:\n\nTarget trial (ideal RCT)\n\n* Adult (≥18 years of age) patients with history of primary invasive cancer under surveillance at Memorial Sloan Kettering Cancer Center (MSK).\n* Completion of an exercise survey (baseline) as part of MSK Cancer Survivorship Program and completion of a historical survey in the MSK Cancer Survivorship Program 9-15 months (time th) prior reporting non-exercising status \\[i.e., reporting \\\u003C10 metabolic equivalent-hours per week (MET-h\u002Fweek)\\]. Patients completing an additional exercise survey between th and baseline are excluded.\n* No evidence of recurrent or metastatic disease in the 15 months prior to the baseline exercise assessment\n* Completion of all definitive primary adjuvant therapy (e.g., chemotherapy, radiotherapy, targeted therapy) at least 3 months prior to completion of the historical exercise survey in a MSK Cancer Survivorship Program. Adjuvant hormonal therapy is permitted at any time.\n* Undergoing surveillance in the Cancer Survivorship Program at MSK\n\nEmulation using observational data\n\n* Adult (≥18 years of age) cancer survivors under surveillance at Memorial Sloan Kettering Cancer Center (MSK) between 2011 and 2023.\n* Assessment of self-reported exercise status via completion of an exercise survey as part of MSK Cancer Survivorship Program standard intake (baseline assessment).\n* Non-exercising (i.e., reporting \\\u003C5 MET-h\u002Fweek) via completion of an exercise survey as part of MSK Cancer Survivorship Program standard intake 9-15 months prior to the baseline exercise assessment (historical exercise survey).\n* Documented history of the following absolute contraindications to moderate-intensity exercise at any time prior to the baseline exercise assessment, assessed using the Elixhauser ICD codes: Congestive heart failure, valvular disease, chronic pulmonary disease, or renal failure.\n* No evidence of recurrent or metastatic disease via radiological or pathological in EMR in the 15 months prior to the baseline exercise assessment.\n* Completion of all definitive primary adjuvant therapy (e.g., chemotherapy, radiotherapy, targeted therapy) at least 3 months prior to completion of historical exercise survey (i.e., at least 3 months prior to t-1) as part of MSK Cancer Survivorship Program standard intake. Adjuvant endocrine therapy is permitted.",true,"ALL","18 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","This protocol is a retrospective study using observational data to conduct a target trial emulation to examine the association of exercise on cancer specific endpoints and other clinical outcomes in cancer survivors.",[24,25,26,27,28],"Survivorship","Recurrent","Recurrence","Cancer","Remission",[24,30,31,32,33,34,35],"Exercise","cancer survivor","adult cancer survivor","no evidence of disease","20-101","Memorial Sloan Kettering Cancer Center","RECRUITING","2026-04-27",{"date":39,"type":40},"2026-04-28","ACTUAL",{"date":42,"type":40},"2020-03-19",{"date":44,"type":20},"2027-03-19",{"name":35,"class":46},"OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":85,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100495785","phase-2-mt2021-08t-cell-receptor-alphabeta-depletion-pbsc-transplantation-for-heme-malignancies-100495785","NCT05735717","MT2021-08T Cell Receptor Alpha\u002FBeta Depletion PBSC Transplantation for Heme Malignancies","Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha\u002FBeta Depletion (A\u002FB TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies","Inclusion Criteria:\n\n* Histological confirmation of hematological malignancies\n* Acute leukemias\n* Acute Myeloid Leukemia (AML) and related precursor neoplasms\n* Favorable risk AML is defined as having one of the following:\n* Acute lymphoblastic leukemia (ALL)\u002Flymphoma\n* Myelodysplasia (MDS) IPSS INT-2 or High Risk (i.e. RAEB, RAEBt) or Refractory Anemia with severe pancytopenia, transfusion dependence, or high risk cytogenetics or molecular features.\n* Age 60 years of age or younger at the time of consent\n* Karnofsky performance status ≥ 70% or Lansky play score 50% for ≤16 years of age.\n* Adequate organ function\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Active uncontrolled infection within 1 week of starting preparative therapy\n* Known seropositive for HIV or known active Hepatitis B or C infection with detectable viral load by PCR.\n* Any prior autologous or allogeneic transplant\n* CML blast crisis\n* Active central nervous system malignancy","60 Years",{"count":56,"type":20},70,"INTERVENTIONAL",[59],"PHASE2","This is a phase II, open-label, prospective study of T cell receptor alpha\u002Fbeta depletion (TCR α\u002Fβ TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies. This is a safety\u002Ffeasibility study of the investigational procedure\u002Fproduct.",[62,63,28,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84],"Hematologic Malignancy","Acute Leukemia","Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia","AML","TP53","Intrachromosomal Amplification of Chromosome 21","Cytogenetic Abnormality","CNS Leukemia","Minimal Residual Disease","Myelodysplasia","Juvenile Myelomonocytic Leukemia","Somatic Mutation","PTPN11 Gene Mutation","N-RAS Gene Amplification","Neurofibromatosis 1","NF1 Mutation","CBL Gene Mutation","Monosomy 7","Chromosome Abnormality","Fetal Hemoglobin","Lymphoblastic Lymphoma","High Grade Non-Hodgkin's Lymphoma, Adult",[86,87,88,89,90,91,92,93,94,95,96,97],"Bu","Flu","G-CSF","GFSR","aGVHD","HCT","MAC","Mel","PBSCT","PTLD","RECIST","TCR","2026-03-31",{"date":100,"type":40},"2026-04-06",{"date":102,"type":40},"2023-05-11",{"date":104,"type":20},"2030-11-30",{"name":106,"class":46},"Masonic Cancer Center, University of Minnesota",1,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":115,"minAge":17,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":57,"phases":118,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},"100558629","impact-of-a-multidisciplinary-assessment-in-day-hospitalization-versus-standard-care-on-the-deployment-of-supportive-oncology-care-recommended-by-the-personalized-post-cancer-plan-in-patients-at-the-end-of-initial-treatment-for-gynecological-ovarian-and-endometrial-cancer-endometrial-cancer-100558629","NCT06553612","Impact of a Multidisciplinary Assessment in Day Hospitalization Versus Standard Care on the Deployment of Supportive Oncology Care Recommended by the Personalized Post-cancer Plan in Patients at the End of Initial Treatment for Gynecological Ovarian and Endometrial Cancer Endometrial Cancer","AFTERGYN2","Inclusion Criteria:\n\n* Patient \\> 18 years\n* Patients in remission from first-line treatment of endometrial or ovarian\u002Ftumor\u002Fperitoneal cancer.\n* Patient who has completed her initial treatment; patients on maintenance therapy are eligible.\n* Fluency in French\n* Patient with access to a telephone line\n* Patient affiliated to a social security scheme\n* Signature of informed consent prior to any specific study procedure\n\nExclusion Criteria:\n\n* Any associated medical or psychiatric condition that could compromise the patient's ability to participate in the study\n* Patient with locoregional or metastatic recurrence\n* Patient deprived of liberty, under guardianship or curatorship\n* Simultaneous participation in a therapeutic clinical trial","FEMALE",{"count":117,"type":20},268,[119],"NA","This project proposes a structuring of supportive oncology care for the recovery phase after gynecological cancer (ovarian\u002Ftrope\u002Fperitoneum or endometrium). Patients will be divided into three groups based on the identification of oncological support care needs. Patients with supportive oncology care needs will be randomized into two groups: the experimental group, receiving a personalized post-cancer plan with a multidisciplinary assessment of supportive oncology care needs in a day hospital and coordinated follow-up by the referring study nurse, and the control group, receiving a personalized post-cancer plan without a day hospital. Randomization will be stratified according to tumor location (ovary vs. endometrium), use of supportive oncology care during treatment, and treatment center. Patients with no need for supportive oncology care will be followed in an observational cohort. The main objective is to identify and manage the supportive oncology care needs of patients in remission from endometrial or ovarian cancer to improve their quality of life and post-treatment follow-up. A medico-economic analysis will be performed.",[122,28],"Gynecologic Cancer",[124,125],"supportive oncology care","personalized post-cancer plan","2026-01-07",{"date":128,"type":40},"2026-01-08",{"date":130,"type":40},"2024-06-07",{"date":132,"type":20},"2028-06-07",{"name":134,"class":46},"Centre Francois Baclesse",13,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":57,"phases":146,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":107},"100550819","changing-trunk-muscle-activation-in-patients-with-recurrent-low-back-pain-in-remission-100550819","NCT06452030","Changing Trunk Muscle Activation in Patients With Recurrent Low Back Pain in Remission","MAS","Inclusion Criteria:\n\n1. People between 18-65 years old\n2. Having recurrent non-specific low back pain (LBP) in remission at enrolment:\n\n   * At least 2 episodes of LBP\u002Fyear, with an 'episode' implying pain lasting a minimum of 24 hours which is preceded and followed by at least 1 month without LBP\n   * Minimum LBP intensity during episodes should be ≥2\u002F10 on a numeric rating scale (NRS) from 0 to 10\n   * During remission the NRS intensity for LBP should be 0-1\u002F10.\n3. Having a dominant flexion movement pattern\u002F neutral movement pattern\n\nExclusion Criteria:\n\n1. People \\\u003C18 years old or \\>65 years old\n2. Having any other type of non-specific LBP (acute, subacute, chronic).\n3. Having an active extension movement pattern\n4. Having any type of blood clotting disorder\n5. People with upper-limb complaints that prevent them from exerting (maximum) force with their arms or hands.\n6. People that received specific sensorimotor control training or fascia-training in the previous year\n7. People with serious underlying conditions (e.g., multiple sclerosis) or severe scoliosis\n8. People with a history of spine surgery\n9. Pregnant women and women who have given birth in the year before enrolment","65 Years",{"count":145,"type":20},55,[119],"The first aim of the study is to investigate the effects of a single therapy session on trunk muscle activation and lumbopelvic sensorimotor control in persons with recurrent low back pain in remission.\n\nThe second aim of the study is to examine the convergent validity of (in)voluntary multifidus activation by means of inspection and palpation during two clinically assessed lumbopelvic sensorimotor control tests in persons with recurrent low back pain in remission. The convergent validity will be examined by calculating the relationship between (1) the clinical score of (in)voluntary multifidus activation, (2) back muscle activation during the same tests measured simultaneously with electromyography and (3) trunk muscle activation during other functional movements measured with electromyography.\n\nThe third aim of the study is to investigate the convergent validity of a left-right discrimination test by calculating the relationship between (1) the left-right discrimination test, (2) position-reposition test, (3) the Fremantle Back Awareness Questionnaire and (4) the Photograph Series of Daily Activities Scale.",[149,28],"Recurrent Low Back Pain",[151,152,30,153],"Low back pain","Motor control","Randomised Controlled Trial","2024-06-10",{"date":156,"type":40},"2024-06-11",{"date":158,"type":40},"2024-03-29",{"date":160,"type":20},"2025-10-01",{"name":162,"class":46},"University Ghent"]